Status:
COMPLETED
Stress & Resilience Study
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
Stanford University
University of California, San Francisco
Conditions:
Stress
Stress, Psychological
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Goal 1: The investigators will quantify lifetime stress burden and examine mechanisms linking Adverse Childhood Experiences (ACEs) and health. The investigators will quantify the early life and total ...
Detailed Description
Aim 1: The investigators will quantify lifetime stress burden and examine mechanisms linking Adverse Childhood Experiences (ACEs) and health. The investigators will quantify the early life and total l...
Eligibility Criteria
Inclusion
- A participant must meet all of the following criteria to be eligible to participate in this study:
- Be able to understand and agree to comply with planned study procedures in English.
- Participants must be aged 18 or over.
- Participants must reside in the state of California.
Exclusion
- A participant who meets any of the following criteria will be excluded from participation in this study:
- History of disease(s):
- Has a positive test result for human immunodeficiency virus (HIV) types 1 or 2 antibodies.
- Has had a heart attack or stroke within the past year.
- Has had and/or been treated for any type of cancer in the past two years.
- Medication(s):
- Participants who check off any of the following medications and/or treatment listed below over the past month will be excluded in the study.
- Prednisolone (e.g., Omnipred, Pred Mild, Pred Forte, Orapred ODT, Veripred 20, Millipred DP)
- Prednisone (e.g., Prednisone Intensol, Deltasone, Rayos)
- Betamethasone (e.g., Celestone Soluspan, Sernivo, Diprolene AF, ReadySharp Betamethasone, Betaloan SUIK, Beta-1)
- Dexamethasone (e.g., Ozurdex, Maxidex, DexPak 6 Day/10 day/13 Day, LoCort, ZonaCort, ReadySharp dexamethasone, DoubleDex)
- Hydrocortisone (e.g., Hydrocort, Alphosyl, Aquacort, Cortef, Cortenema, and Solu-Cortef)
- Methylprednisolone (e.g., Depo-Medrol, Solu-Medrol, Medrol, ReadySharp Methylprednisolone, P-Care D80, and P-Care D40)
- Deflazacort (e.g., Emflaza)
- Immunomodulators
- Cyclosporine (Sandimmune, Neoral, Gengraf, Restasis MultiDose)
- Tacrolimus (Protopic, Envarsus XR, Astagraf XL, Prograf)
- Methotrexate (Rheumatrex, Trexall, Otrexup (PF), Xatmep, Rasuvo, Mexate, MTX)
- Azathioprine (Immuran, Azasan)
- Mercaptopurine (6-MP, Purinethol, Purixan)
- Other Immunomodulators not listed above
- Monoclonal antibody therapy
- Infliximab (Remicade)
- Etanercept (Enbrel, Benepali, Erelzi)
- Adalimumab (Humira)
- Secukinumab (Cosentyx)
- Tofacitinib (Xeljanz)
- Rituximab (Rituxan)
- Other Monoclonal antibody therapy not listed above
- Intravenous immunoglobulin treatment (IVIG)
Key Trial Info
Start Date :
June 30 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 30 2024
Estimated Enrollment :
712 Patients enrolled
Trial Details
Trial ID
NCT06063174
Start Date
June 30 2023
End Date
October 30 2024
Last Update
April 15 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California, Los Angeles
Los Angeles, California, United States, 90024